Meyerhardt Jeffrey A, Tepper Joel E, Niedzwiecki Donna, Hollis Donna R, Schrag Deborah, Ayanian John Z, O'Connell Michael J, Weeks Jane C, Mayer Robert J, Willett Christopher G, MacDonald John S, Benson Al B, Fuchs Charles S
Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
J Clin Oncol. 2004 Jan 1;22(1):166-74. doi: 10.1200/JCO.2004.04.172.
Prior studies have demonstrated superior outcomes after a curative surgical resection of rectal cancer at hospitals where the volume of such surgeries is high. However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain.
We studied a nested cohort of 1,330 patients with stage II and stage III rectal cancer participating in a multicenter, adjuvant chemoradiotherapy trial. We analyzed differences in rates of sphincter-preserving operations, overall survival, and cancer recurrence by hospital surgical volume.
We observed a significant difference in the rates of abdominoperineal resections across tertiles of hospital procedure volume (46.3% for patients resected at low-volume, 41.3% at medium-volume, and 31.8% at high-volume hospitals; P <.0001), even after adjustment for tumor distance from the anal verge. However, this higher rate of sphincter-sparing operations at high-volume centers was not accompanied by any increase in recurrence rates. Hospital surgical volume did not predict overall, disease-free, recurrence-free, or local recurrence-free survival. However, among patients who did not complete the planned adjuvant chemoradiotherapy (270 patients), those who underwent surgery at low-volume hospitals had a significant increase in cancer recurrence (adjusted hazard ratio, 1.94; 95% CI, 1.01 to 3.72; P =.04 for the trend) and a nonsignificant trend toward increased overall mortality (P =.08) and local recurrence (P =.10). In contrast, no significant volume-outcome relation was noted among patients who did complete postoperative therapy.
Using prospectively recorded data, we found that hospital surgical volume had no significant effect on rectal cancer recurrence or survival when patients completed standard adjuvant therapy. Sphincter-preserving surgery was more commonly performed at high-volume centers.
先前的研究表明,在直肠癌根治性手术量高的医院进行手术后,患者的预后更好。然而,由于这些研究往往缺乏关于肿瘤和治疗特征以及癌症复发的详细信息,这种关系的本质仍不确定。
我们研究了1330例II期和III期直肠癌患者的巢式队列,这些患者参与了一项多中心辅助放化疗试验。我们分析了不同医院手术量下保肛手术率、总生存率和癌症复发率的差异。
我们观察到,即使在调整了肿瘤距肛缘的距离后,不同医院手术量三分位数组的腹会阴联合切除术率仍存在显著差异(低手术量医院的患者为46.3%,中等手术量医院为41.3%,高手术量医院为31.8%;P<.0001)。然而,高手术量中心更高的保肛手术率并未伴随着复发率的任何增加。医院手术量并不能预测总生存期、无病生存期、无复发生存期或局部无复发生存期。然而,在未完成计划辅助放化疗的患者(270例)中,在低手术量医院接受手术的患者癌症复发显著增加(调整后的风险比为1.94;95%CI,1.01至3.72;趋势P=.04),总死亡率增加(P=.08)和局部复发(P=.10)的趋势不显著。相比之下,完成术后治疗的患者中未观察到显著的手术量-预后关系。
利用前瞻性记录的数据,我们发现当患者完成标准辅助治疗时,医院手术量对直肠癌复发或生存没有显著影响。高手术量中心更常进行保肛手术。